New pill takes aim at Hard-to-Treat cancers

NCT ID NCT07030257

Recruiting now Disease control Sponsor: Tasca Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This trial tests an experimental drug called CP-383 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The drug is taken daily by mouth and works by blocking a process cancer cells need to grow. The study has two parts: first, finding the safest dose, and then checking if that dose shrinks tumors in specific cancer types. About 150 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CP-383 (a drug that blocks a key step cancer cells need to make new DNA)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 150 participants, so the drug may not work or may cause serious side effects. It is too soon to know if it will help.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer colorectal carcinoma colorectal neoplasm head and neck cancer head and neck squamous cell carcinoma malignant pancreatic neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic neoplasm small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER COLORECTAL CARCINOMA HEAD AND NECK (HNSCC) NON-SMALL CELL LUNG CANCER PANCREATIC CANCER, ADVANCED OR METASTATIC SMALL CELL LUNG CANCER ( SCLC ) SOLID TUMOR MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Florida Cancer Specialists-Lake Nona
RECRUITING

Orlando, Florida, 32827, United States
NEXT Oncology - Dallas
RECRUITING

Dallas, Texas, 75039, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Taylor Cancer Research Center
RECRUITING

Maumee, Ohio, 43537, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.